Zheng Quan Ri Bao Wang·2025-10-28 14:13Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. reported a revenue decline of 4.91% year-on-year for the first three quarters of 2025, totaling CNY 29.393 billion, while innovative drug revenue increased by 18.09% to over CNY 6.7 billion, indicating a strategic focus on innovation-driven growth [1][2]. Group 1: Financial Performance - For the first three quarters of 2025, Fosun Pharmaceutical achieved a total revenue of CNY 29.393 billion, reflecting a year-on-year decrease of 4.91% [1]. - Innovative drug revenue reached over CNY 6.7 billion, marking an 18.09% increase compared to the previous year [1]. Group 2: Innovation and Product Development - In Q3 2025, several self-developed innovative drugs made significant progress in mainstream markets, including the approval of a new indication for the small molecule CDK4/6 inhibitor, Fuzhengning, for specific breast cancer patients in China [2]. - The self-developed Dushuan injection received approval in the U.S. and EU, becoming the first domestically developed Dushuan to be approved overseas, covering all indications previously approved for the original drug [2]. - The CAR-T product, Brexucabtagene autoleucel, had its drug registration application accepted by the National Medical Products Administration in September 2025 for treating adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia [2]. Group 3: Strategic Initiatives - On October 28, 2025, Fosun Pharmaceutical announced plans to spin off its vaccine business platform for a listing on the Hong Kong Stock Exchange to enhance its competitive edge in the vaccine sector [3]. - The company signed a partnership agreement to invest CNY 100 million in a target fund focusing on strategic emerging sectors, including chemical innovation drugs, biopharmaceuticals, high-end medical devices, and traditional Chinese medicine [3]. - Fosun Pharmaceutical is establishing a nuclear medicine platform, Xingrui Jingxuan, to develop integrated diagnostic and therapeutic nuclear medicine products, emphasizing its commitment to innovation and resource optimization [3].